OT

OnKure Therapeutics, Inc.

OKUR·NASDAQ

$4.47

+8.5%
HealthcareBiotechnology

OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors. The company was incorporated in 2011 and is based in Boulder, Colorado.

At a Glance

Live Snapshot
Market Cap$61.12M
EPS-4.4000
P/E Ratio-1.02
Earnings Date08/11/2026

okur

Other Current Liabilities

Last Annual Value

3.94M

3-Year CAGR

39%

5-Year CAGR

-3%

10-Year CAGR

-1%

OT

OnKure Therapeutics, Inc. Competitors Analysis of Other Current Liabilities

OKUR · NASDAQ
CompanyOther Current Liabilities
CAGR 3Y
CAGR 5Y
CAGR 10Y
3.94M
33.3%-8.7%N/A 
-5.16B
N/AN/AN/A
3.67M
9.8%13.3%53.4%
13.53M
26.6%15.4%N/A
-1.87M
N/AN/AN/A
11.74M
19.4%26.6%N/A
0.00
N/AN/AN/A
12.26M
-4.1%-10.7%25.1%
OT

OnKure Therapeutics, Inc. Fair Value Envelope

OKUR · NASDAQ

Our analysis suggests that OKUR has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.47, this represents a potential HIDDEN relative to our calculated worth for OnKure Therapeutics, Inc..

Intrinsic Value
Current Price: $4.47